Pds Biotechnology Stock Story

PDSB -  USA Stock  

USD 8.99  0.86  8.73%

It looks like Regeneron Pharmaceuticals will be up for a correction faster as its share price went up 0.43% today to Pds Biotechnology's 9.34%As many rational traders are trying to avoid healthcare space, it makes sense to go over Pds Biotechnology Corp a little further and understand how it stands against Regeneron Pharmaceuticals and other similar entities. We are going to analyze some of the competitive aspects of both Pds Biotechnology and Regeneron.
Published over a month ago
View all stories for Pds Biotechnology | View All Stories
Is Regeneron more volatile than Pds Biotechnology Corp (NASDAQ:PDSB)?
By analyzing existing basic indicators between Pds Biotechnology and Regeneron, you can compare the effects of market volatilities on both companies' prices and check if they can diversify away market risk if combined in one of your portfolios. You can also utilize pair trading strategies for matching a long position in Regeneron with a short position in Pds Biotechnology. Check out our pair correlation module for more information.

Let's begin by analyzing the assets.
One of the ways to look at asset utilization of Pds Biotechnology is to check how much profit was generated for every dollar of assets it reports. Pds Biotechnology holds a negative application of assets of -41.05 pct., losing $0.41 for each dollar of assets held by the company. Inadequate asset utilization implies the company is being less effective with each dollar of assets it holds. Put it differently, asset utilization of Pds Biotechnology Corp shows how discouraging it operates for each dollar spent on its assets.

How important is Pds Biotechnology's Liquidity

Pds Biotechnology financial leverage refers to using borrowed capital as a funding source to finance Pds Biotechnology Corp ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Pds Biotechnology financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between Pds Biotechnology's total debt and its cash.

How Pds Biotechnology utilizes its cash?

To perform a cash flow analysis of Pds Biotechnology, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Pds Biotechnology is receiving and how much cash it distributes out in a given period. The Pds Biotechnology cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities.

Acquisition by Hill Matthew C of 202800 shares of Pds Biotechnology subject to Rule 16b-3

Legal trades by Pds Biotechnology insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
Pds Biotechnology insider trading alert for grant of stock option (right to buy) by Hill Matthew C, Chief Financial Officer, on 20th of October 2021. This event was filed by Pds Biotechnology Corp with SEC on 2021-10-20. Statement of changes in beneficial ownership - SEC Form 4 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

Another Deeper Perspective

Cash and Equivalents Breakdown

Lets now check Pds Biotechnology cash and equivalents. In accordance with the recently published financial statements, Pds Biotechnology Corp has 28.84 M in Cash and Equivalents. This is 96.49% lower than that of the Healthcare sector and 93.55% lower than that of the Biotechnology industry. The cash and equivalents for all United States stocks is 98.93% higher than that of Pds Biotechnology. As for Regeneron Pharmaceuticals we see cash and equivalents of 3.91 B, which is much higher than that of the Biotechnology

3.9 B
PDSB28.84 Million0.66
Sector447.12 Million10.19
REGN3.91 Billion89.15

Pds Biotechnology current price slip can leaving investors with little time to react

Current sortino ratio is at 0.12.
As of the 16th of October 2021, Pds Biotechnology holds the Semi Deviation of 3.36, coefficient of variation of 964.94, and Risk Adjusted Performance of 0.0899. Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Pds Biotechnology, as well as the relationship between them. Put it differently, you can use this information to find out if the company will indeed mirror its model of past market data, or the prices will eventually revert. We are able to interpolate and collect nineteen technical drivers for Pds Biotechnology Corp, which can be compared to its competitors. Please check Pds Biotechnology Corp information ratio, value at risk, as well as the relationship between the Value At Risk and expected short fall to decide if Pds Biotechnology Corp is priced some-what accurately, providing market reflects its current price of 12.33 per share. Given that Pds Biotechnology has jensen alpha of 0.4276, we recommend you to check out Pds Biotechnology Corp's recent market performance to make sure the company can sustain itself at a future point.

Our Bottom Line On Pds Biotechnology Corp

Whereas some firms in the biotechnology industry are either recovering or due for a correction, Pds Biotechnology may not be as strong as the others in terms of longer-term growth potentials. With a somewhat neutral outlook on your 90 days horizon, it may be better to hold off any trading activity and neither take over new shares of Pds Biotechnology nor exit your existing holdings in the Stock. It seems the expected volatility has not yet been fully factored into the current price. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Pds Biotechnology.

Editorial Staff

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Ellen Johnson do not own shares of Pds Biotechnology Corp. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com